FibroGen (NASDAQ:FGEN – Get Free Report) and Roche (OTCMKTS:RHHBY – Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the ...

Novo Nordisk alleges Singaporean biotech KBP Biosciences made misleading statements before the two firms inked a licensing ...

The week has ended with a flurry of M&A in the drug industry, with Cosette Pharmaceuticals agreeing to buy Australia's Mayne ...

AstraZeneca will obtain the full rights to Roxadustat in China, FibroGen said, adding that it will retain the US and other ...

The company, now based in North Beach, has lost more than $2 billion over 29 years. Its only approved drug, called roxadustat ...

AstraZeneca will gain full rights for roxadustat in China where it is approved to treat anaemia seen with chronic kidney ...

This brief covers various health news including U.S. FDA's misinterpreted banned words policy, New York's lawsuit against vape distributors for targeting teens, President Trump's meeting with pharma ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The deal involves an enterprise value of $85 million plus approximately $75 million in net cash held by FibroGen in China at the time of closing, totaling around $160 million. This strategic move will ...

FibroGen sells its China unit to AstraZeneca for $160 million, extending its cash runway into 2027 and advancing its ...

FibroGen today announced the sale of its China subsidiary to UK pharma major AstraZeneca for around $160 million, with the ...

The $160 million acquisition of a FibroGen subsidiary expands AstraZeneca’s foothold in China while the company works through ...